Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma  by Flores, Raja M et al.
General
Thoracic Surgery
Positron emission tomography defines metastatic disease
but not locoregional disease in patients with malignant
pleural mesothelioma
Raja M. Flores, MDa
Timothy Akhurst, MDb
Mithat Gonen, PhDc
Steven M. Larson, MDb
Valerie W. Rusch, MDa
Background: Computed tomography and magnetic resonance imaging often fail to
predict resectability in patients with malignant pleural mesothelioma. Small studies
suggest that fluorodeoxyglucose-positron emission tomography may improve stag-
ing. We analyzed our experience to determine more definitively the potential utility
of fluorodeoxyglucose-positron emission tomography.
Methods: Patients with malignant pleural mesothelioma who underwent fluorode-
oxyglucose-positron emission tomography scanning were identified from an insti-
tutional database. All patients fasted and received a minimum of 10 mCi of
F-18-fluorodeoxyglucose. Whole-body emission studies were acquired, followed by
whole-body transmission studies, allowing iterative reconstruction. Blinded review
of positron emission tomography scans was performed for clinical staging, which
was then correlated with surgical and pathologic findings. Sensitivity and specificity
were determined for tumor and nodal status.
Results: From 1998 to 2002, 63 patients underwent positron emission tomography
scans, 60 preoperatively and 3 to assess disease recurrence after surgery. Increased
fluorodeoxyglucose uptake was seen in all but 1 tumor, which was very early stage
(IA). Positron emission tomography findings yielded sensitivities of only 19% and
11% for tumor and nodal status, respectively. However, a high standard uptake
value in the primary tumor correlated with the presence of N2 disease. Positron
emission tomography correctly identified supraclavicular N3 or M1 disease in 6
patients.
Conclusions: Positron emission tomography does not identify the local extent of
tumor or mediastinal nodal metastases reliably but detects extrathoracic metastases,
thereby obviating inappropriate thoracotomy. Further studies of the association
between tumor standard uptake value and the presence of N2 disease are warranted.
Malignant pleural mesothelioma (MPM) is an uncommon tumorthat is difficult to evaluate radiologically because of its pro-pensity to infiltrate locally along tissue planes. Computedtomography (CT) and magnetic resonance imaging (MRI) areused to stage MPM but often fail to detect tumor invasion ofthe chest wall and diaphragm, as well as the presence of
mediastinal nodal metastases.1,2 The treatment of early stage disease often involves
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surgical resection by either extrapleural pneumonectomy or
pleurectomy/decortication.3,4 However, approximately 20%
to 30% of patients undergo exploratory thoracotomy with-
out resection because of the unreliability of current imaging
modalities in identifying locally advanced or metastatic
disease.2,5 Improved methods of determining resectability
are needed to minimize the number of patients subjected to
exploratory thoracotomy without resection.
Two studies suggested that MPM shows an increased
uptake of fluorodeoxyglucose-positron emission tomogra-
phy (FDG-PET) scanning, and that PET may be useful in
staging this disease.6,7 However, these studies were too
small to yield definitive information. We hypothesized that
the functional tumor imaging provided by PET scanning
might improve locoregional staging in patients undergoing
preoperative evaluation or identify otherwise unsuspected
extrathoracic disease, thereby avoiding inappropriate surgi-
cal exploration. Therefore, we reviewed our experience with
FDG-PET scanning in MPM.
Methods
Clinical Data
All patients with biopsy-proven MPM who underwent FDG-PET
scanning were identified from our institutional database. Clinical
data on these patients were also extracted from a prospective
institutional database. The pathologic diagnosis of mesothelioma
was confirmed by review of histology and relevant immunohisto-
chemical stains. All patients were considered for surgery if they
had potentially resectable lesions identified by CT scan of the chest
and upper abdomen and adequate cardiopulmonary function to
tolerate the planned resection.
PET Evaluation
PET scans were acquired on dedicated bismuth germinate-based
systems, including the GE Advance (GE Medicals Systems, Mil-
waukee, Wis), Siemens HR, and Siemens Biograph scanners
(CPS Innovations, Knoxville, Tenn). All patients were instructed
to fast for 6 hours before the administration of FDG. After a
minimum of 45 minutes postinjection of at least 10 mCi of FDG,
whole-body emission scans were performed, with rod source-
based transmission scans to allow for iterative reconstruction with
segmented attenuation correction.
A central review of all PET scans was performed by a single
nuclear medicine physician who was blinded to all clinical infor-
mation. Patients were clinically staged by PET using the Interna-
tional Mesothelioma Interest Group TNM staging system, the
staging system for MPM which is now accepted by the American
Joint Commission on Cancer and the Union Internationale Contre
le Cancer.8-10 The standard uptake value (SUV) was calculated
according to standard methods based on the uptake of FDG in
grams per milliliter corrected for the injected dose of FDG ad-
justed for the patient’s weight. To calculate the maximal SUV in
the tumor, we thresholded the images electronically such that only
the hottest voxel of the tumor was seen. A region of interest was
drawn around the hottest voxel on the transaxial slice of the
iteratively reconstructed images, and the SUV maximal value,
corrected for body weight, was recorded.
Statistical Methods
The SUV was calculated for each tumor. The Wilcoxon test was
then used to determine the relationship between tumor histologic
subtype, and the mean SUV for all tumors was studied. A P value
of less than .05 was considered statistically significant.
Sensitivity and specificity on the basis of PET readings were
calculated for tumor (T) and nodal (N) status. Sensitivity was
defined as the number of patients with positive PET scan results
divided by the total number of patients found to have positive
results on surgical and pathologic examination. Specificity was
defined as the number of patients with negative PET scan results
divided by the total number of patients found to have negative
results on surgical and pathologic examination. Positive predictive
value was defined as the number of true positive findings by PET
scan divided by the total number of positive PET scans. Negative
predictive value was defined as the number of true negative PET
findings divided by the total number of negative PET scan results.
Receiver operator characteristic (ROC) curves were calculated
on the basis of SUV for both N and T status. The area under the
curve (AUC) was calculated to determine the utility of SUV in
predicting each status.
Results
Demographics
From April 1998 to February 2002, 63 patients with biopsy-
proven MPM underwent FDG-PET scanning. These pa-
tients included 52 men and 11 women, with a median age of
66 years (range 35-82 years). There were 34 right-sided
tumors and 29 left-sided tumors. There were 44 patients
with tumors of epithelial histology, 16 with the mixed
subtype and 3 with tumors of the fibrosarcomatous subtype.
Types of Surgical Intervention
Sixty patients underwent PET scans before definitive sur-
gical intervention. Three patients underwent PET scans
during follow-up to determine disease status after extrapleu-
ral pneumonectomy (n 2) or pleurectomy/decortication (n
 1). Twenty-six patients underwent extrapleural pneumo-
nectomy, 10 patients underwent pleurectomy/decortication,
19 patients underwent exploratory thoracotomy without re-
section, 1 patient underwent wedge resection after pleurec-
tomy, 2 patients underwent mediastinoscopy, and 2 patients
underwent supraclavicular lymph node biopsy. At least 1
month before the PET scan, 10 patients had received induc-
tion chemotherapy and 18 patients had prior talc pleurode-
sis.
The patients who did not have a resection performed had
disease invading the mediastinum or chest wall (T4 tumor).
This reflects our institutional policy of offering patients
exploration whenever preoperative imaging studies indicate
potentially resectable disease and not performing an ex-
trapleural pneumonectomy in cases unless all gross tumor
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can be removed. We have a low threshold for exploration in
this patient population because of the inaccuracies of CT
scan and MRI in predicting resectability. We consider a
patient as unresectable when there is diffuse chest wall
invasion or disease invading mediastinal structures (eg, the
vena cava) that would not be removed by an extrapleural
dissection. Our goal in surgery is to rid the patient of all
gross disease. If this is not possible with an extrapleural
pneumonectomy, then the procedure is not performed, re-
gardless of the feasibility.
Analysis of PET Scan Results
Of the patients who underwent PET scans before surgical
intervention, 59 of 60 had FDG-18 uptake in the primary
tumor. The median SUV of the primary tumor was 6.6
(range 1.7-23). The single patient who had no increased
uptake on PET scan was found to have minimal parietal
pleural disease (stage IA) at thoracoscopy.
PET findings were correlated with tumor histology. The
mean SUV for epithelial tumors (n 39) was 6.67 ( 2.78)
and 7.37 ( 5.82) for the mixed histology tumors (n  14).
These were not significantly different (P .88). There were
only 2 sarcomatous tumors with SUVs of 3.4 and 4.1.
Of the 53 patients who underwent both FDG PET eval-
uation of T status and surgical and pathologic evaluation, 21
ultimately had unresectable tumors as the result of tumor
invading the chest wall or mediastinum (T4 status), as
shown in Table 1. The sensitivity of PET in identifying T4
status was 19% (95% confidence interval [CI]: 5%-42%).
The specificity was estimated to be 91% (95% CI: 75%-
98%). The positive predictive value of PET was 57% (95%
CI: 18%-90%), but there were only 7 patients classified as
T4 by PET. The negative predictive value, on the other
hand, was 63% (95% CI: 48%-77%).
PET scans were also analyzed to determine if the SUV
correlated with T status. The mean SUV for the patients
with T0 to T3 tumors was 6.7 ( 2.9) and was also 6.7 (
3.9) for patients who had T4 disease. A receiver operating
characteristic (ROC) curve based on SUV was constructed
to determine the accuracy of FDG-PET in defining T4
disease (Figure 1). The AUC was 53% ( 9%), indicating
that FDG-PET SUV did not accurately predict T status.
A correlation of PET findings to tumor N status was only
possible in 31 patients, because the remaining patients tech-
nically could not have complete surgical evaluation by
mediastinal lymph node dissection. As shown in Table 2,
there was a total of 9 patients who had mediastinal nodal
metastasis (N2 disease), but only 1 of these patients was
correctly identified by PET. Two patients were considered
to have hilar nodal metastasis (N1 disease), and the remain-
ing patients were not considered to have any nodal metas-
tasis by PET. Therefore, the sensitivity of PET in detecting
nodal metastasis was 11% (95% CI: 0%-48%), and the
specificity was 86% (95% CI: 65%-97%). The positive
predictive value of PET was 25% (95% CI: 1%-81%), and
the negative predictive value was 70% (95% CI: 50%-86%).
PET scans were also analyzed to determine if SUV of the
primary tumor correlated with N status. The mean SUV for
the 18 patients classified as N0 and N1 was 5.3  2.1, and
the mean SUV for the 9 patients who were classified as N2
positive was 8.6  3.4. An ROC curve based on primary
tumor SUV was constructed to determine the utility of FDG
PET in defining N2 disease (Figure 2). The AUC was 78%
TABLE 2. PET assessment of N status compared with the
pathological N status
N status by PET
N0 and N1 N2
Total no.
patients
Pathologic N status N0 and N1 19 3 22
N2 8 1 9
Total no. patients 27 4 31
N, Nodal.
TABLE 1. PET assessment of T status compared with sur-
gical and pathologic staging of T status
T status by PET
T0–T3 T4
Total no.
patients
Surgical/pathologic T status T0–T3 29 3 32
T4 17 4 21
Total no. patients 46 7 53
PET, Positron emission tomography; T, tumor.
Figure 1. Receiver operator characteristic (ROC) curve of primary
tumor standard uptake value (SUV) as a predictor of tumor T4
status. The area under the curve (AUC) of 53% indicates a poor
accuracy of positron emission tomography (PET) in predicting
tumor status.
Flores et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 1 13
G
TS
 10%. The ROC curve is better for the N status than for
the T status, and there seems to be an association between
increased SUV and nodal disease. This indicates that pa-
tients who have a higher SUV in the primary tumor are
more likely to have mediastinal nodal metastasis.
PET correctly identified 6 patients who had unresectable
tumor because of extrathoracic disease. Open biopsy con-
firmed peritoneal metastasis in 1 patient, supraclavicular
lymph node biopsy identified N3 disease in 2 patients, MRI
confirmed pelvic bone metastasis in 1 patient, and PET
identified N3 disease in 1 patient who developed a contralat-
eral effusion while awaiting supraclavicular lymph node
biopsy (and subsequent thoracentesis demonstrated meta-
static mesothelioma). One patient with N3 disease, but no
gross adenopathy on CT scan, underwent thoracotomy and
proved to be unresectable on the basis of diffuse chest wall
invasion.
PET failed to accurately detect disease in 3 patients. One
patient had a false-negative scan that failed to detect a 1-cm
nodule of mesothelioma; the small size of the nodule on the
CT scan was presumed to be the reason for the lack of
detection by PET. Two patients had false-positive findings
on PET scan (1 patient had a supraclavicular node that
showed inflammation, which may have accounted for the
false-positive results).
Discussion
Inaccurate clinical staging by current imaging modalities
hinders the diagnosis and treatment of MPM. CT and MRI
fail to identify unresectable disease in approximately 20%
to 30% of patients. Our results confirm that most cases of
MPM show increased FDG uptake on PET. We observed
only 1 patient whose tumor did not have increased FDG
uptake at initial diagnosis, and this patient was found to
have an extremely early stage tumor. In addition, a false-
negative PET scan was obtained in a follow-up patient who
developed a minimal amount of recurrent pleural tumor.
Therefore, PET may fail to detect minimal tumor burden in
MPM, and a negative PET scan does not absolutely rule out
the presence of disease. In contrast with studies suggesting
that PET can be used to distinguish between benign and
malignant pleural disease,7 our results indicate that thora-
coscopic biopsy may be necessary in such cases for defin-
itive diagnosis.
The tumor histologic subtype does not seem to influence
PET findings. Both epithelial and mixed histology tumors
had similar SUVs. Although both of these tumors had lower
SUVs than tumors of other histologies, there were too few
tumors of sarcomatous subtype for analysis.
Given the lack of spatial localization provided by PET, it
is not surprising that we did not reliably identify patients
who were unresectable by virtue of T4 disease. The poor
sensitivity of PET indicates that it should not be used to
make decisions about the resectability of the primary tumor.
It remains to be seen whether the newly available combined
PET/CT scanners will provide better anatomic tumor defi-
nition.
We elected not to evaluate the influence of CT scan on
staging. This study was performed specifically to correlate
PET scan findings as a single modality with surgical patho-
logic findings. For staging to be considered, it would have
required a retrospective review of different quality CT scan-
ners from different institutions performed at different time
periods other than the PET scan. Because the CT scans were
performed in a non-uniform fashion, we would not have had
the consistency that would be required to answer the spe-
cific question in a scientific manner. Combined PET/CT
scanners are now available in many institutions and may
provide better spatial localization and, therefore, improved
staging of locoregional disease. This warrants future inves-
tigation.
The SUV was also not a good predictor of the T4 status.
On the basis of the ROC curve, it seems that the SUV has
no relationship at all to T status. The SUV probably reflects
the rate of tumor growth and biology rather than a particular
stage at the time of diagnosis.
It has been proposed that PET is useful in the determi-
nation of N status.6 Improved nodal staging would be valu-
able in MPM because of the known adverse impact of N2
disease on prognosis.4 However, our experience indicates
that PET also does not reliably predict N status. This is not
surprising given the difficulties in spatial resolution within
the mediastinum. Pleural tumor involving or abutting the
mediastinum will show increased FDG uptake and can
easily be misinterpreted as nodal disease. There were a total
of 9 patients with N2 disease, and PET did not identify 8.
Therefore, any management decision based on PET findings
Figure 2. ROC curve of SUV of the primary tumor as a predictor of
N2 status. The AUC of 78% seems potentially useful in predicting
the presence of mediastinal nodal disease.
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of N2 disease should be confirmed by surgical pathologic
evaluation.
A high SUV in the primary tumor seems to correlate with
the presence of mediastinal nodal metastasis. This may
simply reflect the propensity of more metabolically active
tumors to metastasize to mediastinal nodes. This is an
interesting preliminary finding. Further investigation is
needed to determine if there is a specific SUV level at which
mediastinal nodal metastasis is likely to be present. Such
information may be of potential use in selecting patients for
surgical resection.
Our data indicate that FDG PET may be useful in iden-
tifying extrathoracic disease either preoperatively or in the
setting of potential tumor recurrence. Although these find-
ings warrant confirmation in a larger number of patients, it
is valuable to identify even a small number of patients in
whom surgical intervention may be inappropriate.
This experience builds on that reported in previous stud-
ies. The number of patients in our study is larger than in
previously published studies, but it is still a somewhat
heterogenous patient cohort. Additional studies in still
larger numbers of patients are warranted. Future studies
should investigate our observation that high primary tumor
SUV correlates with N2 disease and could validate the lack
of correlation between SUV and histologic subtype. Inves-
tigations of the accuracy of combined PET/CT scanning
should also be undertaken to determine whether this imag-
ing modality leads to better definition of T and N status.
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Discussion
Dr David J. Sugarbaker (Boston, Mass). I very much appre-
ciated the opportunity to read the article by Dr Flores and his group
at Memorial regarding this interesting study of PET and mesothe-
lioma. I think it is important to look for different modalities to
understand preoperatively the extent of disease in mesothelioma,
and I suggest that the findings in this particular study are not
unexpected. The difficulty of defining the preoperative stage in
mesothelioma is derived from the fact that the geographical dis-
tribution of the tumor, unlike other malignancies, is very diffuse,
and all of the modalities, including MRI and CT scan (which
preceded PET), have had difficulty in defining preoperatively the
appropriate stage. Nevertheless, this study suggests that there are
some limited useful applications of PET in mesothelioma, partic-
ularly in those malignancies that have a high metabolic rate taking
up a lot of the markers; thus, there is the implication of a very high
mitotic index and therefore a higher propensity to spread to the
lymph nodes. Unfortunately, there is a very small group of patients
who will demonstrate distant metastatic disease at the time of
presentation. Nevertheless, in this small group of patients, it seems
that PET has some usefulness.
I have 3 questions for Dr Flores and his group at Memorial,
who obviously have extensive experience with mesothelioma.
First, I believe 21 patients in your series were “open and close,”
unresectable. Given the limited cohort you had, this seems to be a
relatively high unresectability rate. Would you address that and tell
us if there was anything in the MRI, CT, or other aspects of the
preoperative workup that may have indicated that these patients
were indeed unresectable before their exploration? As a sideline to
that question, was there a propensity for these patients to be mixed
or sarcomatous types as opposed to epithelial types?
My second question concerns your statement that MRI is
unreliable in determining resectability. Some years ago at
Brigham, I, Dr Patz, and some of our colleagues in radiology wrote
about the fact that although MRI is somewhat limited, it is the most
useful preoperative staging radiologic modality when coupled with
echocardiography. This is primarily because MRI allows one to
see 2 important areas more easily and accurately than CT scan-
ning: transdiaphragmatic extension of the disease and transmedi-
astinal invasion into structures that are clearly going to render the
patient unresectable. So, I ask you to comment on your use of MRI
and echocardiography at Memorial in the workup of these patients.
Third, would you comment on the presence or absence of chest
pain in your patients who are unresectable? What is your use of
mediastinoscopy in the preoperative workup of these patients? We
have found that even mild chest pain is often the best predictor of
diffuse chest wall invasion by these tumors.
I thank Dr Flores and his group and congratulate them on an
excellent study, which I think contributes to our knowledge of
mesothelioma and to our understanding of the use of PET scanning
in this disease.
Dr Flores. I will start by combining the first and third ques-
tions. In regard to the unresectability rate, many PET scans per-
formed in patients were not obtained uniformly. Initially, more
PET scans were performed in patients who had a higher tumor
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